Clinical Practice Guideline Establishes Standards for Blood-Based ctDNA Assays
This guideline provides comprehensive recommendations for the clinical implementation of circulating tumor DNA assays, covering pre-analytical procedures, analytical components of current technologies, and result interpretation and reporting. The document addresses ctDNA applications including early diagnosis, therapeutic target identification, treatment response monitoring, prognosis evaluation, and minimal residual disease detection. It serves as an essential reference for laboratories integrating ctDNA testing into routine clinical workflows.
The original study
Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays.
- Authors
- Lee JS, Cho EH, Kim B, Hong J, Kim YG, Kim Y, et al.
- Journal
- Annals of laboratory medicine
- Type
- Review, Guideline, Journal Article
- PMID
- 38221747
Original abstract
Circulating tumor DNA (ctDNA) has emerged as a promising tool for various clinical applications, including early diagnosis, therapeutic target identification, treatment response monitoring, prognosis evaluation, and minimal residual disease detection. Consequently, ctDNA assays have been incorporated into clinical practice. In this review, we offer an in-depth exploration of the clinical implementation of ctDNA assays. Notably, we examined existing evidence related to pre-analytical procedures, analytical components in current technologies, and result interpretation and reporting processes. The primary objective of this guidelines is to provide recommendations for the clinical utilization of ctDNA assays.